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Background: Understanding what causes changes in the ﬂux of free fatty acids (FFA) is important to
elucidate the etiology of metabolic syndrome. The ﬁrst aim of this study was to test whether or not
hormones and the autonomic nervous system inﬂuence blood FFA levels. A secondary aim was to test by
means of a multiple group path analysis whether the consumption of fermented red ginseng (FRG; Panax
ginseng) would inﬂuence those causal relationships.
Methods: Ninety-three postmenopausal women (age 50e73 yr) were randomly divided into two groups.
One group (44 women; age, 58.4  5.9 yr; body mass index, 23.6  2.5 kg/m2) was supplied placebo
capsules and the other group (49 women, age 58.4  5.5 yr; body mass index, 22.9  2.4 kg/m2) was
supplied FRG capsules. Both prior to and after the study (2 wk), blood samples were collected from the
participants and several blood variables were measured and analyzed.
Results: Squared multiple correlations of FFA were 0.699 in the placebo group and 0.707 in the FRG
group. The unstandardized estimate of estradiol (E2) for FFA was 0.824 in both groups.
Conclusion: The path coefﬁcients of cortisol and the branchial pulse for FFA were signiﬁcantly different
between the FRG group and the placebo group.
opyright  2014, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Of the primaryenergy sources in the humanbody (carbohydrates,
proteins, and lipids), lipids are the most efﬁcient type of energy
storage (9 kcal/g) and are hence much more prevalent than carbo-
hydrates or proteins as a form of storage [1]. This makes the process
of lipid release a crucial component in understanding human energy
metabolism and pathology. Several studies have reported that the
incidence of metabolic syndrome in postmenopausal women is
higher than inpremenopausalwomenandthat thecausesare related
not only to estrogen levels but also to the levels of other hormones
related to lipid metabolism [2].
The chronic override of free fatty acids (FFA) in the bloodmay be
a risk factor in human energy metabolism. A high level of FFA often
correlates with type 2 diabetes, hypertension, dyslipidemia, insulin
resistance, hyper uric acid, and abnormal ﬁbrinolysis [3]. Obese
individuals commonly show insulin resistance; correspondingly,utrition, Research Institute of Hum
inseng, Published by Elsevier. Opetheir levels of fatty acids are also elevated. The most common cause
of the positive correlations between FFA and several diseases is the
competition between override FFA and carbohydrates in the energy
oxidation process [4]. Boden et al [5] reported that after lipids were
administered to test volunteers, lipid oxidation increased and car-
bohydrate oxidation decreased simultaneously. Compared to
healthy volunteers, diabetic patients showed a 40e55% decrease in
their insulin-stimulated glucose absorption rates [6].
Energymetabolism differs between the postprandial and fasting
states. In the postprandial state, carbohydrates are used as a major
energy source and insulin is released. In the fasting state, adipo-
cytes release triglycerides, which are broken down into FFA and
glycerol, which then enter the circulatory system. During the
overnight fasting period, the burst size of FFA during the daily cycle
is maximized [7].
In a fasting state, over the long term, basal metabolic lipolysis
occurs when insulin levels and catecholamine levels decrease.an Ecology, Seoul National University, Seoul 151-742, Korea.
n access under CC BY-NC-ND license. 
J Ginseng Res 2014;38:97e10598In the short term, acute lipolysis occurs in “ﬁght or ﬂight” (emer-
gency) states. In this state, catecholamines are triggered by the
sympathetic nerve system [8]. In cell membranes, those catechol-
amine signals stimulate b-adrenoreceptors, which activate adenylyl
cyclase via simultaneous G-protein coupled receptors. Adenylyl
cyclase then transforms adenosine triphosphate into cyclic aden-
osine monophosphate (cAMP). The cAMP then binds to the regu-
latory module of the protein kinase A, activating it, which then
phosphates hormone-sensitive lipase (HSL) [9].
Both long- and short-term lipolyses are affected by several
hormones. Glucocorticoid [10], adrenocorticotropic hormone
(ACTH) [11], thyroid hormone, dehydroepiandrosterone [12], in-
sulin [7], and estrogen [13] have all been shown to inﬂuence
lipolysis through the functioning of b-adrenergic receptors, the
production of adenylyl cyclase, the activities of G-proteins, or
changes in cAMP production.
The lipolysis of white adipose tissue is inﬂuenced by the auto-
nomic nervous system as well as the central nervous system. For
example, when the sympathetic nerve directly stimulates the ad-
renal medulla, it causes catecholamine to be released. The cate-
cholamine then stimulates adipocytes to trigger lipolysis. In
addition to this catecholamine pathway, sympathetic nerves
directly innervate within adipose tissue. Cousin et al [14] reported
that the level of lipids in the peritoneum increased after denerva-
tion. This suggests that the sympathetic nervous system inﬂuences
the activity or differentiation of white adipose cells.
Parasympathetic nerves as well as sympathetic nerves showed a
relationwith adipose tissue. Kreier et al [15] reported that when the
parasympathetic nerve was removed, the HSL activity in white
adipose tissue increased. However, the absorption of FFA and blood
glucose decreased.
Given that the direct measurement of autonomic nervous ac-
tivity by micrography is not feasible in a large epidemiological
study, heart rate variability (HRV) is used as the measurement
method for the autonomic nervous system [16]. HRV is measured
by the variation of the beat-to-beat interval. The average R-R is
calculated by 60 divided by the average heart rate in beats/min.
Chang et al [17] showed that HRV is related to several component of
metabolic syndrome (MtS). When they separated 1,298 individuals
into four groups based on the components of MtS, those who had
one or more components of MtS showed a lower standard devia-
tion of the R-R interval compared to a healthy control group.
The recorded use of ginseng dates back 2,000 years. It has been
one of the most popular herbal supplements in Asia, especially in
Korea, China, and Japan. In the USA, ginseng ranked as one of the
top-10 selling herbal supplements in 2003 [18]. The primary
effective components of ginseng are known as ginsenosides, and
these include compound K (CK), Rg3, Rk1, and Rg5, all of which
have a steroidal skeleton.
In the results of this study, CK served as the ligand of gluco-
corticoid receptor (GR) [19] and Rg3 functioned as the ligand of
estrogen receptor (ER) [20], which implies a possible effect of
ginseng on lipolysis. In fact, when CK was administered to a 3T3-L1
adipocyte cell line, the storage of triglycerides was suppressed. On
the other By contrast, Rg1 stimulated triglyceride storage in adi-
pocytes [21]. Rg3, Rk1, and Rg5 treatments in 3T3-L1 suppressed
lipid accumulation [22].
As well as the reported effects of ginseng on FFA, red ginseng has
also been shown to have a beneﬁcial effect on insulin and glucose
regulation. Vuksan et al [23] reported that red ginseng consump-
tion improved insulin and glucose regulation in type 2 diabetes
patients. Lee et al [24] showed that red ginseng has a beneﬁcial
effect on insulin sensitivity. We also reported that fermented red
ginseng (FRG) showed a serial causal effect on the level of hor-
mones, insulin resistance, and insulin levels. In an analysis of theeffects of hormones on glucose blood levels, the difference between
the FRG group and the placebo group was due to the level of
aldosterone [25].
According to an experiment with mice, ginsenosides stimulated
an acetylcholine release in the terminal of cholinergic neurons [26].
In a human study with 120 adult men, wild ginseng increased the
activity of the autonomic nerves and increased the heart rate [27].
Theﬁrst aimof this studywas to test thehypothesis that hormones
(including insulin) and the branchial pulse rate (the autonomic ner-
vous system activity) affected the ﬂux of FFA in the blood. For this
analysis, a path model was established and estimates of the model ﬁt
and thehypothesiswere then tested. The second aimof this studywas
to testwhether FRGconsumption affects the relationshipbetween the
independent variables of several hormones and the autonomic ner-
vous system and the dependent variable of FFA.
The study hypotheses were: (1) ACTH, growth hormone (GH),
E2, glucocorticoid, tri-iodothyronine (T3), thyroid-stimulating
hormone, and/or insulin inﬂuence the release of FFA; (2) the
brachial pulse rate, which represents the activity of the autonomic
nervous system and affects the release of FFA from adipocytes; and
(3) the consumption of FRG changes the rate of FFA release, and this
release is mediated by FRG on ER or GR.
2. Materials and methods
2.1. Participants and study design
This study was approved by the Institutional Review Board of
Sahmyook University (Seoul, Korea). The study participants were
117 postmenopausal women (age 50e73 yr) who were recruited
from four Catholic churches. Participants with any disease,
including diabetes, cardiovascular disease, dyslipidemia, and kid-
ney disease, were excluded. None of the study participants took any
supplements for 2 wk prior to or during the experiment.
Anthropometric parameters were used to evaluate and catego-
rize the 117 participants, who then had their brachial and ankle
blood pressure and brachial and ankle blood pulse measured twice,
once in the supine position and again after a 10-min rest period.
Although the brachial and ankle pressures and pulse rate vary ac-
cording to the spectrum of life activity, the pressure and the pulse
in the supine position can be considered as the pressure and the
pulse of a participant in a resting state.
After overnight fasting, blood and urine samples from the 117
participants were collected from 8:00 AM to 10:00 AM. The study
participants were then divided into two groups according to the
double-blind method of drawing lots. One groupwas supplied with
capsules containing FRG powder (Biﬁdo Inc., Gangwon-do, Korea),
and the other group was supplied with placebo capsules containing
edible starch for 2 wk. Because a hypothesis of this study was that
ginsenosides are ligands of nuclear receptors and that the effects of
a nuclear receptor can beginwithin 2 h, we considered that 2 wk of
FRG consumption was sufﬁcient.
The ingredients of the FRG capsules were as follows: crude
saponin, 258.6 mg/g; compound K, 57.05 mg/g; Rg3, 53.85 mg/g;
Rh2, 11.97 mg/g; Rg2, 5.72 mg/g; Rh1, 2.99 mg/g; and Rb1,
0.023 mg/g. The total weight of the FRG capsule powder was 2.1 g.
After 2 wk, 24 women dropped out of the study; therefore, 93
women (49 in the FRG group and 45 in the placebo group) partic-
ipated in the second blood sample collection. The reported cause of
departure for 23 of the womenwas individual personal reasons not
related to FRG consumption. One woman left the experiment after
reporting insomnia associatedwith her consumption of FRG (Fig.1).
Blood samples were measured at the Green Cross Reference
Laboratory (Gyeonggi-do, Korea). The methods of sample analysis
are listed in Appendix I.
Table 1
Anthropometric Data of Participants
Mean  SD p
FRG (n ¼ 49) Placebo (n ¼ 44)
Age (yr) 58.5  5.5 58.6  5.8 0.944
Weight (kg) 56.9  6.7 57.7  6.9 0.559
Height (cm) 157.7  5.3 156.6  5.4 0.311
BMI (kg/m2) 22.88  2.39 23.55  2.51 0.189
Waist circumference (cm) 32.7  2.3 33.1  2.4 0.397
Hip circumference (cm) 36.9  2.0 37.3  2.1 0.284
Waist/hip 0.89  0.03 0.89  0.04 0.965
BMI, body mass index; FRG, fermented red ginseng; SD, standard deviation.
Fig. 1. Flow of this study. The 117 volunteers who participated in the ﬁrst blood sample collection were divided into two groups with random double-blind trials. The blood samples
were collected between 8:00 AM and 10:00 AM. One group took fermented red ginseng (FRG) capsules three times/day (2.1 g/d) for 2 wk. The other group took a placebo containing
starch. Ninety-three women participated in the second blood sample collection. Ninety of the 93 participants were postmenopausal, and three were perimenopausal.
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matched according to age, height, weight, and body mass index.
2.2. Statistical analyses
The arithmetic means of the variables from both groups were
analyzed by SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). The out-
liers of insulin and E2 were excluded and considered as missing
values. Unmeasured variables were considered as random missing
values and 10 datasets were generated by a multiple imputation
method [28].
Path analysis has several advantages in that several variables and
multiple groups can be analyzed simultaneously; moreover, the
effects of decomposition andmodelﬁtness can be assessed.Weused
path analysis as well as traditional statistics including mean com-
parisons in this study. The pathmodelwas analyzedwithMplus 6.11
(Muthén&Muthén, LosAngeles, CA, USA). The data in this report are
part of an FRG study that was conducted in Seoul, Korea in 2010.
Only the data relevant to this analysis are presented in this report.
3. Results
3.1. Anthropometric data
There were no signiﬁcant differences in age, weight, height, and
body mass index between the FRG group and the placebo group
(Table 1).
3.2. Arithmetic mean comparisons
Hormones showed circadian variation and seasonal variation.
Despite the fact that a double-blind random sampling method was
utilized in this study, therewas sampling error. Therefore, the analyses
of thehormonesandothervariables requiredcrosstalkvalidationandacomprehensive assessment. We analyzed the mean comparisons of
samples between the FRG group and the placebo group with three
statistical methods: an analysis of covariance (ANCOVA) in the second
samples (ANCOVA comparison), independent t tests of the second
samples (second sample t test), and independent t tests of the differ-
ences between the second andﬁrst samples (difference t test; Table 2).
In the ANCOVA comparison, themean values of ACTH, cortisol, T3, and
FFA did not show a signiﬁcant difference between the two groups,
whereas the level of insulinwas lower in the FRG group than it was in
the placebo group (p¼ 0.04). In the difference t test, the level of insulin
was found to be lower in the FRG group than in the placebo group
(p ¼ 0.01). In the ANCOVA comparison, the level of dehydroepian-
drosterone was higher in the FRG group than it was in the placebo
group (p¼ 0.05), and the same resultwas shown in thedifference t test
(p¼ 0.03). In the ANCOVA comparison, the levels of E2 (p¼ 0.06) and
GH (p¼ 0.06) were higher in the FRG group than in the placebo group,
but the differences were not statistically signiﬁcant (Table 2).3.3. Path model
The baseline model was established based on reports in the
literature. The Wald test was conducted to test the hypothesis of
Table 2
Comparison of Hormones and Free Fatty Acid Between the Fermented Red Ginseng (FRG) Group and the Placebo Group
Markers Sample Groups Mean  SD (n) p1) (p2)) D2nd e 1st
Mean  SD (n) p1)
ACTH (pg/mL) 1st Placebo 19.6  10.1 (43) 0.712
FRG 20.6  13.2 (49)
2nd Placebo 20.4  10.1 (44) 0.321 2.3 (43) 0.52
FRG 22.7  11.8 (49) (0.34) 0.9 (49)
Cortisol (mg/dL) 1st Placebo 11.4  3.3 (43) 0.064
FRG 9.9  4.2 (49)
2nd Placebo 11.2  3.5 (44) 0.531 0.2 (43) 0.13
FRG 10.8  3.8 (49) (0.52) 0.9 (49)
Estradiol (pg/mL) 1st Placebo 22.6  17.3 (20) 0.693
FRG 20.6  15.1 (20)
2nd Placebo 14.5  7.3 (19) 0.083 7.4 (19) 0.06*
FRG 18.3  7.3 (19) (0.06*) 1.0 (19)
GH (ng/mL) 1st Placebo 1.4  1.3 (20) 0.424
FRG 1.9  2.6 (20)
2nd Placebo 0.9  1.2 (20) 0.40 (20) 0.50
FRG 1.8  1.4 (20) (0.06*) 0.06 (20)
DHEAS (mg/dL) 1st Placebo 71.5  28.9 (43) 0.412
FRG 66.7  26.8 (49)
2nd Placebo 65.2  31.4 (44) 0.871 6.2 (43) 0.03**
FRG 66.2  29.1(49) (0.05*) 0.5 (49)
Insulin (mU/mL) 1st Placebo 6.5  7.2 (43) 0.667
FRG 7.1  6.2 (49)
2nd Placebo 6.4  3.6 (43) 0.838 1.0 (43) 0.01**
FRG 6.3  2.9 (48) (0.04**) 0.2 (48)
Glucose (mg/dL) 1st Placebo 91.9  8.9 (43) 0.211
FRG 89.9  6.8 (49)
2nd Placebo 89.6  6.8 (44) 0.128 2.2 (43) 0.85
FRG 87.4  7.1 (49) (0.31) 2.5 (49)
FSH (mIU/mL) 1st Placebo 73.8  25.6 (20) 0.261
FRG 65.6  19.6 (20)
2nd Placebo 74.0  24.3 (20) 0.387 0.1 (20) 0.44
FRG 68.0  18.5 (20) (0.68) 2.4 (20)
LH (mIU/mL) 1st Placebo 37.8  14.7 (20) 0.068*
FRG 30.6  8.8 (20)
2nd Placebo 38.8  14.8 (20) 0.036** 1.0 (20) 0.56
FRG 30.3  9.0 (20) (0.30) 0.3 (20)
TSH (mIU/mL) 1st Placebo 2.7  1.6 (20) 0.058*
FRG 1.9  1.0 (20)
2nd Placebo 2.8  1.8 (20) 0.298 0.1 (20) 0.41
FRG 2.3  1.2 (20) (0.80) 0.4 (20)
T3 (pg/dL) 1st Placebo d
FRG d
2nd Placebo 912.1  912 (20) 0.12 (20) 0.33
FRG 935.6  123 (20) (0.86) 0.06 (20)
FFA (mEq/L) 1st Placebo 662.4  232.1 (43) 0.901
FRG 656.8  197.3 (49)
2nd Placebo 640.0  223.7 (44) 0.653 23.5 (43) 0.61
FRG 660.3  217.0 (49) (0.61) 3.8 (49)
Brachial Pulse rate (beats/min) 1st Placebo 70.1  8.4 (48) 0.654
FRG 69.4  9.5 (44)
2nd Placebo 68.5  8.5 (48) 0.957 0.6 (47) 0.494
FRG 68.4  8.5 (43) (0.829) 1.7 (44)
* p < 0.1.
** p < 0.05.
*** p < 0.01.
D2nd e 1st, second sample minus ﬁrst sample; (n), number of samples; ACTH, adrenocorticotropic hormone; DHEAS, dehydroepiandrosterone; FSH, follicle stimulating
hormone; GH, growth hormone; LH, luteinizing hormone; SD, standard deviation; T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.
1) Independent t test.
2) Analysis of covariance.
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for each path. The path of cortisol on FFA and the path of the
brachial pulse rate on FFA both showed a signiﬁcant difference
between the two groups (Table 3).
The ﬁnal model was then established (Fig. 2 and Table 4). The
path of cortisol on FFA and the path of the brachial pulse rate on FFA
were measured freely, whereas the other paths were analyzed
with equality constraints (Fig. 2). Therefore, the values of the
unstandardized coefﬁcients of the path of cortisol on FFA and the
values of the unstandardized coefﬁcients of the path of the brachial
pulse rate on FFAwere two in both cases, and the values of the otherunstandardized coefﬁcients were one (Fig. 2). The ﬁnal model’s
goodness of ﬁt was good, as the root mean square error of
approximation was 0.000 and the comparative ﬁt index was 1.000.
When the effects of several independent variables on the FFA
levels were compared with standardized coefﬁcients, the path
coefﬁcients of E2 on FFA were highest at 0.678 in the FRG group
and 0.656 in the placebo group.
The standardized coefﬁcients of cortisol on FFA were 0.387 in
the placebo group, whereas it was 0.233 in the FRG group.
Therefore, when cortisol increased by a standardized deviation
(3.5 mg/dL), the level of FFA increased by 0.387 standard deviations
Table 3
Path Coefﬁcients of Baseline Model and the Values of Wald Test
Path Group Unstandardized estimate Standardized estimate Wald test
From To c2D(1)
ACTH Cortisol FRG 0.448  0.096*** 0.556  0.099*** 0.056
Placebo 0.413  0.114*** 0.479  0.116***
TSH T3 FRG 0.537  0.202 *** 0.475  0.168*** 2.566
Placebo 0.135  0.119 0.217  0.194
FSH LH FRG 0.610  0.216*** 0.506  0.135*** 0.712
Placebo 0.920  0.269*** 0.600  0.128***
FSH Estradiol FRG 0.473  0.309 0.311  0.195 0.091
Placebo 0.328  0.498 0.252  0.359
LH Estradiol FRG 0.208  0.243 0.160  0.184 0.631
Placebo 0.102  0.255 0.125  0.271
Insulin FFA FRG 0.347  0.114*** 0.338  0.101*** 2.644
Placebo 0.007  0.158 0.007  0.132
Cortisol FFA FRG 0.253  0.144* 0.250  0.140* 10.133***
Placebo 0.457  0.152*** 0.386  0.127***
Estradiol FFA FRG 0.865  0.153*** 0.701  0.106*** 0.095
Placebo 0.795  0.165*** 0.667  0.107***
GH FFA FRG 0.347  0.186** 0.298  0.141** 3.304*
Placebo 0.144  0.234 0.088  0.140
ACTH FFA FRG 0.068  0.111 0.085  0.139 0.452
Placebo 0.181  0.128 0.177  0.125
T3 FFA FRG 0.056  0.291 0.032  0.178 0.188
Placebo 0.086  0.273 0.037  0.114
DHEAS FFA FRG 0.296  0.108*** 0.240  0.097** 2.287
Placebo 0.016  0.160 0.016  0.128
TSH FFA FRG 0.370  0.282 0.206  0.165 3.147*
Placebo 0.196  0.241 0.132  0.168
Brachial Pulse rate FFA FRG 0.677  0.199*** 0.462  0.110*** 5.152*
Placebo 0.107  0.168 0.071  0.111
SMC of FFA FRG 0.760***
Placebo 0.733***
* p < 0.1.
** p < 0.05.
*** p < 0.01.
ACTH, adrenocorticotropic hormone; DHEAS, Dehydroepiandrosterone; FFA, free fatty acid; FRG, fermented red ginseng; FSH, follicle stimulating hormone; GH, growth
hormone; LH, luteinizing hormone; SMC, squared multiple correlations (R2smc); T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.
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when cortisol increased by a standardized deviation (3.8 mg/dL), the
level of FFA decreased by 0.233 standard deviations
(0.233  217.0 mEq/L ¼ 50.6 mEq/L) in the FRG group (Table 4).
Squared multiple correlation (SMC; R2smc) refers to the square
value of the standardized estimate and SMC signiﬁes the explana-
tion ability of the independent variables on the ﬂuctuation of the
dependent variables. For example, the standardized estimate of the
brachial pulse rate on FFA was 0.081 and the SMC of the brachial
rate on FFAwas 0.01 (1%¼ 0.0812) in the placebo group, whereas in
the FRG group the estimate of the brachial pulse rate on FFA was
0.464 and the SMC of the brachial rate on FFA was 0.215
(21.5%¼ 0.4642). The standardized estimates of ACTH on FFA and T3
on FFAwere both below 0.1, demonstrating no signiﬁcant inﬂuence
on the concentration of FFA in the ﬁnal model (Table 4).
The SMC values of FFA were 0.699 (p < 0.01) in the placebo
group and 0.707 (p < 0.01) in the FRG group. When the brachial
pulse variable was excluded from the ﬁnal model, the SMC of FFA
changed to 0.671, which did not show a signiﬁcant change in the
placebo group. However, the SMC of FFA in the FRG group
decreased by 0.500, which implies the importance of the brachial
pulse rate on FFA release in the FRG group.
4. Discussion
4.1. E2 and FFA
The accumulationpattern for postmenopausalwomen is different
from that for men [29]. In females, the major locations of fat accu-
mulation are in the lower body and in subcutaneous tissue, whereas
in males fat accumulates in the upper body and in the organs of theabdominal cavity (visceral fat). The fat accumulation area is impor-
tant in relation to the onset of MtS [30] because released FFA from
abdominal adipocytes are directly transported to the liver via the
hepatic portal vein, resulting in a decrease in insulin clearance and an
increase in the synthesis of triglycerides and very low density lipo-
protein [31]. Therefore, the movement and accumulation effect of
lipids by E2 are important for a proper understanding of the lipid
metabolic process.
The effects of E2 on lipolysis are different between subcutane-
ous adipocytes and abdominal adipocytes. For example, E2 treat-
ment decreased the level of lipolysis in the adipocytes, which
mediated an increased number of a2Aeadrenergic receptors,
whereas E2 treatment did not showany effect on the lipolysis of the
abdominal adipocytes [32]. In addition, abdominal adipocytes
showed a low level of a-adrenoreceptors and a high level of b-
adrenoreceptors when compared to the level of b-adrenoreceptors
in subcutaneous adipocytes [33]. These differences in the ratio with
regard to the adrenoreceptor type may help to explain differences
in gender-dependent spatial fat accumulation.
In the present study, the positive relationship between the
concentrations of E2 and FFA may have been due to the fasting
times and the lowered E2 levels of the postmenopausal women in
the present study design. Because blood samples were collected
after 8 h of overnight fasting, the migration effect of FFA by lipo-
protein lipase from the circulatory system to the adipocytes can be
ignored. However, it was possible to infer that genome indepen-
dent lipolysis by E2 could stimulate HSL and inositol triphosphate
activities. Even though it is well known that Rg3 acts as the ligand
of ERs and Rg3 was a high ratio of ginsenosides in this study, the
effect of E2 on FFA did not show a signiﬁcant difference between
the groups.
Fig. 2. The equality constrained ﬁnal model. The path of cortisol on free fatty acid (FFA) and the path of brachial pulse rate on FFA were freely analyzed and the other paths were
constrained for equality between the fermented red ginseng (FRG) group and the placebo group. The numbers on the arrow line represent the unstandardized estimates of path.
ACTH, adrenocorticotropic hormone; CFI, comparative ﬁt index, DHEAS, dehydroepiandrosterone; FFA, free fatty acid; FSH, follicle stimulating hormone; GH, growth hormone; LH,
luteinizing hormone; R2, squared multiple correlations (SMC); RMSEA, root mean square error of approximation; T3, tri-iodothyronine; TSH, thyroid-stimulating hormone.
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Djurhuus et al [34] reported that when a physiologically high
level of cortisol was injected into the adipose tissue, the level of
blood FFA increased by 60%, as mediated by lipolysis stimulation. In
the ﬁnal model here, the path coefﬁcient value of cortisol on FFA
was positive (p ¼ 0.002) in the placebo group, whereas the path
coefﬁcient value was negative (p ¼ 0.082) in the FRG group.
Therefore, it may be presumed that CK consumption acts as a
competitive inhibitor with cortisol of the GR in this study.
In a postprandial state, insulin is released and suppresses the
functions of HSL and lipolysis in adipocytes. In a fasting state,
however, the level of insulin decreases, and the levels of cortisol
and growth hormone increase, which in turn stimulates the
expression of HSL [35]. The proper expression of HSL is important in
the regulation of blood glucose. HSL-deﬁcient mice cannot release a
proper level of FFA and thus enter into an insulin-resistant state
[36]. However, in the present study, the growth hormone and FFA
showed a signiﬁcant negative relationship. These results may be
due to the decreased level of GH of the postmenopausal women
owing to the natural process of aging. In fact, the explanation ability
levels (SMC) of GH on the FFA concentration results were only 1% in
the placebo group and 2% in the FRG group.
4.3. Brachial pulse rate and FFA
Although several studies have reported that the activity of the
sympathetic nervous system is related to MtS [17,37], the exact
mechanism of this has yet to be elucidated. Jeon et al [38] reported
that when crude saponin, including ginsenoside, was intravenouslyinjected into rats, their heart rates increased. Because GR and ER are
present in the brain stem area, it may be presumed that CK and Rg3,
ligands of GR and ER, regulate the autonomic nervous system via
the central nervous system. Therefore, consecutively, brain stems
that have GR and ER inﬂuenced by CK and Rg3 could have an effect
on how FFA is released in adipocytes. If so, it would be of interest to
assess whether CK or Rg3 has the strongest effect on the brachial
pulse rate in this study. ER-a is present in the autonomic nerve
center of the brain stem, which regulates the cardiovascular system
[38]. When estrogen was administered into this area, autonomic
nerve regulation of the heart improved and the level of sympathetic
activity decreased [39]. Furthermore, when estrogen was injected
into the brain of an ovariectomized rat, its heart rate decreased [40].
GR is highly expressed in the dorsal hindbrain area and is
especially prominent in the nucleus of the solitary tract [41]. These
areas are centers of cardiovascular regulation. When cortisol was
injected into the dorsal hindbrain of a rat, its heart rate increased
within 3 days [42]. Therefore, because the autonomic effect on FFA
was increased in the FRG group, CK was shown to have a stronger
effect in the FRG group as compared to the placebo group.
4.4. Counteraction between cortisol and the brachial pulse
In the ﬁnal path model (Fig. 2 and Table 4), two paths showed
signiﬁcant differences between two groups, and the signiﬁcance
levels were changed between the two paths and two groups. In this
case, the signiﬁcance levels of the path coefﬁcients of cortisol to FFA
were signiﬁcant in the placebo group (p ¼ 0.002) but were not
signiﬁcant in the FRG group (p ¼ 0.082). However, the signiﬁcant
level of the brachial pulse on the FFA path was not signiﬁcant in the
Table 4
Path Coefﬁcients of Equality Constrained Final Model
Path Group Unstandardized estimate Standardized estimate
From To Estimates  SE p Estimates  SE p
ACTH GC Placebo 0.433  0.073*** 0.000 0.497  0.084*** <0.001
FRG 0.543  0.085*** <0.001
TSH T3 Placebo 0.267  0.117** 0.022 0.383  0.135*** 0.005
FRG 0.255  0.134** 0.057
FSH LH Placebo 0.722  0.164*** 0.000 0.504  0.105*** <0.001
FRG 0.568  0.105*** <0.001
FSH E2 Placebo 0.398  0.329 0.227 0.291  0.242 0.230
FRG 0.276  0.230 0.230
LH E2 Placebo 0.007  0.164 0.968 0.002  0.165 0.989
FRG 0.006  0.142 0.967
Insulin FFA Placebo 0.245  0.096* 0.011 0.188  0.074* 0.011
FRG 0.250  0.097* 0.010
GC FFA Placebo 0.494  0.163*** 0.002 0.387  0.114*** 0.001
FRG 0.229  0.132* 0.082 0.233  0.135* 0.083
E2 FFA Placebo 0.824  0.102*** 0.000 0.656  0.078*** <0.001
FRG 0.678  0.081*** <0.001
GH FFA Placebo 0.211  0.169 0.213 0.108  0.087 0.215
FRG 0.188  0.146 0.197
ACTH FFA Placebo 0.061  0.085 0.471 0.053  0.077 0.485
FRG 0.079  0.110 0.469
T3 FFA Placebo 0.002  0.209 0.994 0.002  0.090 0.980
FRG 0.000  0.125 0.997
DHEAS FFA Placebo 0.155  0.104 0.136 0.114  0.077 0.136
FRG 0.131  0.091 0.151
TSH FFA Placebo 0.197  0.184 0.286 0.122  0.117 0.297
FRG 0.112  0.107 0.294
Brachial
Pulse rate
FFA Placebo 0.135  0.171 0.428 0.081  0.101 0.423
FRG 0.651  0.171*** 0.000 0.464  0.106*** <0.001
SMC of
FFA
Placebo 0.699  0.097*** <0.001
FRG 0.707  0.087*** <0.001
* p < 0.1.
** p < 0.05.
*** p < 0.01.
ACTH, adrenocorticotropic hormone; DHEAS, dehydroepiandrosterone; E2, estradiol; FFA, free fatty acid; FRG, fermented red ginseng; FSH, follicle stimulating hormone; GC,
glucocorticoid; GH, growth hormone; LH, luteinizing hormone; SE, standard error; SMC, squared multiple correlations (R2smc); T3, tri-iodothyronine; TSH, thyroid-stimulating
hormone.
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group (p < 0.001). These results may help researchers establish the
homeostasis levels of essential components such as the major en-
ergy source, FFA, in human physiology.
In the change of signiﬁcance levels, one possible cause of the
“rise and fall” phenomenon between the two groups is the nature
of the glucocorticoid receptors (GR). GRs can be inﬂuenced by ge-
netic variations, redundancies, synergy, crosstalk with other nu-
clear receptors, and by other types of cell signaling. Therefore, in
the path of cortisol to FFA, some test participants showed a sig-
niﬁcant effect of FRG consumption, whereas others did not show a
strong effect. However, for the complimentary path of cortisol to
FFA, the path of the brachial pulse rate to the FFA level showed that
the “rise and fall” phenomenon or the “seesaw” phenomenon be-
tween the cortisol level and the brachial pulse rate was related to
the homeostasis of FFA.
Regarding the methodology, these results are good examples
that show that path analysis may be a useful tool for the simulta-
neous analysis and comparison of the effects of several indepen-
dent variables on dependent variables with multiple groups.
5. Conclusions
Among the several variables in this study, estrogen best
explained FFA ﬂuctuations. The brachial pulse provided a better
explanation of FFA variance in the FRG group than in the placebo
group. Cortisol had a strong effect on FFA release in the placebogroup, but it did not have this effect in the FRG group. These
“seesaw” effects between the brachial pulse rate and cortisol imply
multiple routes of human physiology as regards the homeostasis of
FFA. In conclusion, FRG consumption changed the effect of cortisol
on FFA levels from peripheral tissues to the autonomic nervous
system, whereas the level of FFA and the effects of other variables
on FFA remained unchanged.
The effect of ginsenosides on human physiology depends on the
ratio, dose, and treatment period of the ginsenosides. A study with
a single type of ginsenoside in different environments would
improve our understanding of the effects of hormones on FFA
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Appendix I
Reagents and Instruments
Test name Glucose(S) Insulin Cholesterol total LDL Cholesterol FFA
Test method enzymatic method ECLIA Enzymatic, colorimetry Enzymatic,
colorimetry
ACS-ACOD
(colorimetry method)
Reagent Kit name Glucose Hexokinase Insulin Cholesterol reagent LDL-Cholesterol NEFA HR.II
Company,
nationality
SIEMENS, NY, USA Roche, Mannheim,
Germany
SIEMENS, NY, USA SIEMENS, NY, USA Wako, Osaka, Japan
Analytical
instrument
Instrument name ADVIA MODULAR ANALYTICS ADVIA ADVIA Hitachi
Model name ADVIA 1650 E170 ADVIA 1650 ADVIA 1650 HITACHI 7180
Company,
nationality
SIEMENS, NY, USA Roche, Mannheim,
Germany
SIEMENS, NY, USA SIEMENS, NY, USA HITACHI, Tokyo Japan
Test name TSH T3 FSH LH
Test method CLIA CLIA CLIA CLIA
Reagent Kit name TSH T3 ADVIA CENTAUR FSH ADVIA CENTAUR FSH
company,
nationality
SIEMENS, NY, USA SIEMENS, NY, USA SIEMENS, NY, USA SIEMENS, NY, USA
Analytical
instrument
Instrument name Centaur Centaur ADVIA CENTAUR ADVIA CENTAUR
Model name ADVIA CENTAUR ADVIA CENTAUR ADVIA CENTAUR ADVIA CENTAUR
Company,
nationality
SIEMENS, NY, USA SIEMENS, NY, USA SIEMENS, NY, USA SIEMENS, NY, USA
Test name Cortisol ACTH DHEA-S Estrogen (E2) HGH(S)
Test method RIA IRMA RIA CLIA CLIA
Reagent Kit name Coat-A-count Cortisol ACTH IRMA Coat-A-Count
DHEA-Sulfate
ADVIA
Centaur Estradiol
Immulite
2000 GH
company,
nationality
SIEMENS, LA, USA BRAHMS, Berlin,
Germany
SIEMENS, LA, USA SIEMENS, NY, USA SIEMENS, LA, USA
Analytical
instrument
Instrument name r-counter r-counter r-counter Centaur Immulite
Model name COBRA 5010
QUANTUM
COBRA5010
Quantum
COBRA5010
Quantum
ADVIA Centaur Immulite 2000
Company,
nationality
PACKARD,
Meriden, USA
PACKARD,
Meriden, USA
PACKARD,
Meriden, USA
SIEMENS, NY, USA SIEMENS, LA, USA
ACTH; Adrenocorticotropic hormone, HGH; human growth hormone, DHEAS; Dehydroepiandrosterone, FFA; free fatty acid, FSH; follicle stimulating hormone , LH; luteinizing
hormone, T3; triiodothyronine, TSH; thyroid-stimulating hormone.
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